At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
Denileukin diftitoxdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
In Brief
A Phase 2 clinical trial evaluating Denileukin diftitox for Stage IIIC Melanoma and Stage IV Melanoma. Completed, enrolled 75 participants across 10 sites.
Detailed Summary
The purpose of this study is to determine whether participants with Stage IIIC and Stage IV Melanoma experience benefit when treated with Denileukin diftitox in two different dosing schedules.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage IIIC Melanoma, Stage IV Melanoma
CountriesUnited States
CollaboratorsPharmaBio Development Inc.
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartJun 2010
Primary CompletionApr 2015
TodayJul 2026
First PostedMay 20, 2010
Enrollment StartJun 22, 2010
Primary CompletionApr 7, 2015
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 16.1 years ago
Interventions
Denileukin diftitoxdrug
Denileukin diftitox intravenous infusion over 30-60 minutes.